Wilms Tumor 1 (WT1) (N-Term) Peptide
WT1
Reactivity: Human
Host: Synthetic
WB, BP
-
- Target See all WT1 products
- WT1 (Wilms Tumor 1 (WT1))
- Protein Region
- N-Term
- Origin
- Human
-
Source
- Synthetic
- Application
- Western Blotting (WB), Blocking Peptide (BP)
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-WT1 antibody (Catalog #: ARP37988_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- WT1 (Wilms Tumor 1 (WT1))
- Synonyms
- AWT1 Peptide, EWS-WT1 Peptide, GUD Peptide, NPHS4 Peptide, WAGR Peptide, WIT-2 Peptide, WT33 Peptide, CWT1 Peptide, WT1 Peptide, XWT1a Peptide, wt-1 Peptide, wt1 Peptide, xWT1 Peptide, WT-1 Peptide, gud Peptide, wagr Peptide, wt33 Peptide, xwt1 Peptide, wit-2 Peptide, si:ch211-160j6.3 Peptide, zgc:152697 Peptide, D630046I19Rik Peptide, Wt-1 Peptide, XWT1b Peptide, XeWT1 Peptide, Wilms tumor 1 Peptide, Wilms tumor 1 S homeolog Peptide, wilms tumor 1b Peptide, Wilms tumor protein Peptide, Wilms tumor 1 homolog Peptide, Wilms tumor 1 L homeolog Peptide, WT1 Peptide, wt1.S Peptide, wt1 Peptide, wt1b Peptide, Wt1 Peptide, wt1.L Peptide
- Background
-
WT1 is a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms.This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
Alias Symbols: AWT1, GUD, WAGR, WIT-2, WT33, NPHS4, EWS-WT1
Protein Interaction Partner: AREG,CIAO1,CREBBP,FHL2,PAWR,PAX2,PRKACA,TP53,TP63,TP73,U2AF2,UBE2I,WTAP,WTIP,PAWR,Pawr,TP53,U2AF2,UBE2I,WTAP
Protein Size: 514 - Molecular Weight
- 56 kDa
- Gene ID
- 7490
- NCBI Accession
- NM_000378, NP_000369
- UniProt
- E9PMK7
-
You are here:
